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Abstract 
In response to the recent alarming prevalence of cancer, osteoarthritis and other inflammatory 
disorders, the study of anti-inflammatory and anticancer crude medicinal plant extracts has gained 
considerable attention. Eucomis autumnalis is a native flora of South Africa with medicinal value. It has 
been found to have anti-inflammatory, anti-bacterial, anti-tumor/cancer, anti-oxidative and anti-
histaminic characteristics and produces bulb that have therapeutic value in South African traditional 
medicine. Despite the widely acclaimed therapeutic values of Eucomis autumnalis, its proper 
identification and proper knowledge, morphogenetic factors are yet to be efficiently evaluated. Similar to 
other plants with the same characteristics, E. autumnalis extract may stimulate bone formation and 
cartilage regeneration by virtue of its anti-inflammatory properties. This review provides data presented 
in the literature and tries to evaluate the three subspecies of E. autumnalis, highlighting their 
geographical location in South African provinces, their toxicity effects, as well as their phytochemistry 
and anti-inflammatory properties. Biologically active components, pharmacological importance and 
some environmental factors that can affect E. autumnalis are presented. The review also discussed the 
novel potential roles of E. autumnalis in regenerative medicine. Proper knowledge of the E. autumnalis 
plant and its possible role in bone and cartilage regeneration will help in addressing and clarifying its 
use in the production of drugs and for other therapeutic purposes, especially in the treatment of 
inflammatory diseases and cancer.  
 
Keywords: Medicinal plants, inflammatory diseases, toxicity, phytochemicals, bone regeneration 
 
This is an Open Access article that uses a funding model which does not charge readers or their institutions 
for access and distributed under the terms of the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative 
(http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and 
reproduction in any medium, provided the original work is properly credited. 
Tropical Journal  of Pharmaceutical Research is indexed by Science Citation Index (SciSearch), Scopus, 
International Pharmaceutical Abstract, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African 
Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals 




In developing countries, traditional medicine is 
still used in the primary treatment of many 
diseases, although few of these remedies have 
been reported scientifically in the literature. In 
response to the accelerating rate of cancer, 
osteoarthritis (OA) and obesity worldwide, the 
study of anti-inflammatory and anticancer crude 
medicinal plant extracts has gained considerable 
attention, perhaps because the current available 
treatment methods for these defects are 
expensive, have devastating side effects or are 
incapable of restoring all the normal 
biomechanical characteristics completely in 
damaged human tissues and organs [1-3].   
-----------------------------------------------------------------------------------------------------------------------------------------------------
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The worldwide alarming prevalence of OA, 
arthritis, osteoporosis, atherosclerosis and 
rheumatoid arthritis, with few, if any, current 
effective treatment measures, cannot be 
overlooked. In Canada, 4.5 million people older 
than 15 years have arthritis and it is estimated 
that 7 million people will have arthritis by 2031 
[4]. It has been estimated that 27 million 
Americans will suffer from OA by 2020. Studies 
have shown that joint disease will be at increase 
in South African because 70 % of their women 
are overweight or obese. This paves way for an 
upsurge of joint diseases if no health measures 
are taken [5].  
 
A cell-based approach to using stem cells and 
herbal solutions for stimulation, protection and 
anti-inflammatory purposes in the regeneration 
and repair of bone, tissues, organs and cartilage 
in transplantation is promising both in tissue 
engineering and for therapeutic uses [6]. 
 
According to a World Health Organization (WHO) 
report, 80 % of people in Africa (South Africa) 
depend upon herbal drugs for their therapeutic 
effectiveness [7], yet little is known about 
medicinal plants, their extracts and 
morphogenetic factors. 
 
Indigenous medicinal plants have been used 
traditionally as a major source of drugs for the 
treatment of various illnesses, including OA, 
asthma, cancer, heart disease, tuberculosis, 
swollen ankles and hypertension [8,14,45]. 
Extracted compounds of medicinal plants are 
usually employed as inputs in toxicology, 
phytochemicals, pharmaceuticals and other 
chemical industries [7,8,14]. Proper identification 
and knowledge of medicinal plants and their 
morphogenetic factors is of paramount 
importance. In South Africa, studies have 
documented reports on Eucomis autumnalis 
(E.autumnalis) and other medicinal herbs used in 
ethno-therapy of wound healing, pain relief, 
inflammatory diseases, fractures, teething, 
backache and other ailments [8,14,7,9,10]. E. 
autumnalis is the most commonly used herbal 
remedy for post-operative recovery and the 
treatment of bone fractures [Table 1] in South 
Africa. Table 1 also shows E. autumnalis plant, 
common names, its geographical location and 
some diseases where it has been locally 
employed. 
 
E. autumnalis (Mill.) also known as pineapple lily, 
is native to South Africa. Because of its 
antibacterial and antifungal compounds, the 
bulbs of E. autumnalis are used in Southern 
African traditional medicine. The anti-
inflammatory activity of the E. autumnalis plant 
depends on age, season, fertilization and growth 
conditions [15,17,18]. 
 
Although the therapeutic values of E. autumnlis 
are widely acclaimed (Table 1), they are yet to be 
rigorously evaluated in terms of their safety. 
Many studies have recorded complications 
arising from the administration of some medicinal 
plants. This review evaluates the biologically 
active components and pharmacological 
importance of E. autumnalis. The classification, 
geographical distribution of E. autumnalis 
subspecies and its phytochemical properties are 
also highlighted. This work discusses some 
effects of environmental factors on E. autumnalis 
and its possible role in bone and tissue 
regeneration as well. 
 
Knowledge of the above-mentioned properties of 
E. autumnalis will help in addressing and 
clarifying its use in the production of drugs and 
for other therapeutic purposes, especially in the 
treatment of inflammatory diseases and cancer. 
E. autumnalis plant species are extensively used 
 



















































Alaribe et al 
743 
 
in South Africa for both traditional and 
pharmacological needs because of their anti-
inflammatory and anti-cancer properties and very 




E. autumnalis belongs to the Asparagaceae 
family. It is a deciduous, summer-growing bulb 
plant with very decorative raceme inflorescences 
composed of numerous star-shaped, greenish-
white and sweetly scented flowers. The bulb is 
about 8-10 cm in diameter and ovoid in shape 
[18,33,19,17]. The flowers are produced in mid- 
to late summer (December to February) and the 
fruit is in the form of a trilocular capsule 
containing shiny, black rounded seeds. Its 
specific name, autumnalis, refers to its flowering 
and fruiting time. 
 
E. autumnalis is divided into three subspecies 
and can be identified by the structure of the stalk 
of the inflorescence (peduncle) and geographical 
location, but generally the peduncle is either 
club-shaped or cylindrical. The subclasses of E 
autumnalis are E. autumnalis amaryllidifolia, E. 
autumnalis autumnalis (undulata) and E. 




Figure 1: The three subspecies of E. autumnalis 
medicinal plants. A; E. autumnalis amaryllidifolia, 
B; E.autumnalis undulata and C; E. autumnalis 
clavata 
 
Eucomis undulata and Fritillaria autumnalis 
subsp (cylindrical), are types of E. autumnalis 
subspecies found on mountain slopes, in open 
grassland and forest margins in the Eastern 
Cape, Northern Province, Zimbabwe and Malawi. 
They form a dense rosette of strap-like leaves 
with undulating edges and white or green flowers 
on spikes around 60 cm high.  Eucomis robusta 
and Eucomis clavata subsp (club shape) grow in 
open grassland and marshes in Lesotho, 
KwaZulu-Natal, Mpumalanga, the eastern Free 
State and Gauteng. The leaves of this species 
have margins that are crispy and wavy. Their 
green flowers are creamy green on a stout stem, 
club-shaped and tightly packed. The third 
subspecies of E. autumnalis is Eucomis 
amaryllidifolia subsp. It is a rarer subspecies with 
linear, thick ovate prostrate leaves and a club-
shaped peduncle. These plants are found among 
rocks on the mountain slopes of the Western 
Free State and Eastern Cape [14,20,21,28,17]. 
Apart from South Africa, E. autumnalis can also 
be found in Zimbabwe, Malawi, Botswana and 
California.   
 
Phytochemistry of E. autumnalis 
 
In the genus Eucomus, many constituents such 
as homoisoflavanones and triterpenoid 
glycosides have been isolated from the bulbs of 
several of the species investigated.  The 
homoisoflavanones are usually found in the waxy 
layer between the storage leaves of the bulb and 
the terpenoids in the bulb tissue 
[14,12,16,22,23]. E. autuimnalis species have 
been phytochemically investigated and 
compounds have been profiled. In all, three 
homoisoflavanones, two dibenzo-α-pyrones 
(structure corresponding to xanthones), two 
spirocyclic nortriterpenoids (structure of these 
compounds confirmed by the x-ray structure of p-
bromobenzene sulphate derivative) and an acid 
compound have been isolated (Table 3). 
Moreover, E. autumnalis leaves, bulbs and roots 
are known to inhibit the synthesis of 
prostaglandin, thereby protecting the 





The most popular traditional use of E. autumnalis 
species has been for anti-inflammatory and 
fracture purposes (Table 1), hence they are 
recommended to be used in the manufacturing of 
non-steroidal anti-inflammatory drugs (NSAID). 
The anti-inflammatory capacity of E. autumnalis 
varies according to the part of the plant 
[26,27,12,16]. Generally, anti-inflammatory 
activity in the E. autumnalis plant depends on 
age, season, fertilization and growth conditions 
[17,18,24,25]. 
 
During inflammation, prostaglandins are involved 
and are responsible for the sensation of pain. 
Numerous studies have investigated the anti-
inflammatory effects of E. autumnalis by 
evaluating the efficacy of its extracts for 
prostaglandin synthesis. This in vitro assay tends 
to measure the degree of inhibition of 
Cyclooxygenase enzyme activity. Cyclooxy-
genase exists in two isoforms, COX-1 
Alaribe et al 
744 
 
Table 2: E. autumnalis phytochemical isolated compounds and their general structure  
 
No        Compound 
name 









also been identified from 
the genus Drimiopsis. 
Two types have been 
isolated from E. 
autumnalis (autumnariol). 
 
[12, 14, 30] 
 










                                --  
They are usually found in 
the asparagaceae group. 
Reported first in 1967 
from the genus Eucomis 
and are found 
concentrated in the waxy, 
scale-like layers of the 
bulb. So far, only three 
types have been isolated 
in E. atumnalis. 
 








It is the most common 
class of 
homoisoflavonoids with a 
16-carbon skeleton 
formed. The benzyl 
group is attached at the 
3-position. 
 








In this group, they have 
hydroxyl group attached 
at the 3-position and their 
3-hydroxy-3-benzyl-4-
chromanones occur as a 
mixture of C-3 epimers 
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They are characterized 
by a basic lanosterol 
triterpenoid skeleton 
losing one terminal 
methyl of the side chain. 
Two of these compounds 
have been isolated from 
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and COX-2 [33,27,12,16]. Generally, studies 
have observed E. autumnalis to selectively inhibit 
COX-2, with little interference with COX-1. This 
property/characteristic makes E. autumnalis plant 
extract potentially anti-inflammatory and non-
ulcer genic, hence it is frequently employed by 
traditional healers in wound/fracture healing and 
post-surgery treatment (Table 1). E. autumnalis 
therefore has a considerable interesting quality 
for therapeutic use. 
 
Effects of environmental factors  
 
Plant protection programs, particularly those con-
cerning plants grown for phyto-therapeutics, are 
focused on prophylactic treatments that 
encourage limited use of pesticides negatively 
affecting the environment. The popular bulb of E. 
autumnalis in the South African medicinal trade 
is currently becoming threatened in the wild and 
measures have been taken for its protection to 
counteract the depletion of the wild population.  
 
Studies have observed that seed germination of 
E. autumnalis is influenced by light conditioning, 
cold stratification and a smoke-derived 
compound [34]. Light, temperature, moisture and 
chemical bio-stimulants such as smoke have 
been identified to be among the major 
environmental factors that can influence growth 
and development of seedlings of a number of 
plant species, including E. autumnalis [22,23,34].  
[35] investigated not only the effects of sunlight 
intensity, temperature, watering frequency and 
smoke-water solutions on seedling and bulb 
development, but also the pharmacological 
properties of E. autumnalis bulbs exposed to 
different light conditions, temperature regimes, 
watering frequencies and smoke-water solutions. 
They observed in their study that sunlight 
intensity of 50 % achieved the best developed 
seedlings and bulb sizes, compared to 75 % and 
100 % sunlight. The optimum temperatures for 
seedling development of E. autumnalis were 
found to be 30/15°C. Regular watering frequency 
(three times per week) produced the largest 
bulbs compared to less frequent watering. A 
smoke-water solution at a 1:250 v/v dilution 
stimulated growth and produced the largest bulbs 
when compared to dilutions of 1:500 and 
1:1000 v/v smoke-water.   
For the pharmacological properties against two 
Gram-positive, two Gram-negative and a fungus 
Candida albicans, the result showed an increase 
in the bioactivities of some of the extracts from 
the bulb exposed to different light conditions, 
temperature regimes, watering frequencies and 
smoke-water solutions compared to the control 
bulbs. Antimicrobial activity was also found to be 
very high in acetone extracts when compared to 
water extracts of E. autumnalis [24,34,35]. 
 
Furthermore, heavy metals in the environment 
affect medicinal plant extracts. Soil-plant and 
roots-microbes interactions play vital roles in 
regulating heavy metal movement from the soil to 
edible plant parts. Studies have observed that 
the accumulation of metals by both roots and 
leaves is proportional to the availability of metal 
concentration in the external medium, with 
factors such as reduced biomass, root light, 
shoot length and root length being common 
indicators of heavy metal toxicity [36-38]. Direct 
interaction between the metal and structural 
components in the environment causes visible 
changes at the cell, tissue and organ levels of 
medicinal plants. There is therefore every need 
for conscious site selection and suitable soil 
management to reduce heavy metal uptake by 
medicinal plants [27]. 
 
Over-exploitation is another environmental factor 
that can affect E. autumnalis subspecies. A study 
by [28] showed that the mean size of the bulbs 
decreased significantly between 1995 and 2001. 
This was believed to be an indication of over-
exploitation. Another study also confirmed its 
decline as a result of over-exploitation [29]. 
 
Possible role of Eucomis autumnalis in 
osteoarthritis defects  
 
OA is the best known form of arthritis, a chronic 
inflammatory progressive disorder of the joints, 
characterized by late onset degeneration of 
articular cartilage. Degeneration of articular 
cartilage is marked by the breakdown of cartilage 
matrix proteins. OA causes pain, synovial 
inflammation, joint deterioration and subchondral 
bone alteration [39,40]. It usually affects aged 
people but it can also affect young individuals 
[40-42]. 
 
OA is characterized by relatively few cells with 
low cell mobility owing to the neighboring matrix 
and a limited number of progenitor cells [43,44]. 
These factors retard cartilage regeneration and 
repair; as a result symptoms associated with OA 
occur [45]. The methods currently used to treat 
OA, such as NSAIDS and autologous 
chondrocyte implantation (ACI), mainly revolve 
around, i) pain management, ii) rehabilitation and 
iii) surgery to treat loss of joint function, with 
negative side effects. Furthermore, there are 
problems associated with donor site morbidity, 
difficulty in harvesting a large number of 
chondrocytes without causing substantial 
additional damage and the very high cost of 
treatment [46-48]. A positive outcome has been 
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reported for ACI, involving chondrocyte isolation 
from the cartilage, in vitro expansion and re-
implantation into the cartilage defect by a 
periosteal graft [49,50]. The main disadvantages 
of ACI is the requirement for an invasive surgical 
procedure and the fact that chondrocytes that are 
expanded in culture gradually undergo 
differentiation and lose morphological features 
and specialized functions [51,52]. 
 
However, treatment of OA joints with a wide 
range of growth factors necessary for 
maintenance of cartilage homeostasis in vitro 
and in vivo remain a challenge. One alternative 
or rather a combination approach to the standard 
treatment methods will be to test traditional 
medicinal plants that are likely to stop the 
progress of OA or at least slow it down to a 
satisfactory degree. The drug of choice for 
treating OA should be one that has anti-
inflammatory properties with no side effects. The 
genus E. autumnalis has been found to have 
anti-inflammatory, anti-bacterial, anti-
tumor/cancer, anti-oxidative and anti-histaminic 
characteristics [8,16-19].  Preliminary results 
from our study on articular cartilage 
chondrocytes showed that E. autumnalis is fast-
acting, with maximum cell viability and 
proliferation noticed within the first 24-48 hours of 
incubation. The anti-inflammatory property of E. 
autumnalis indicates its potential to exert a 
chondroprotective effect. Future studies on this 
plant must focus on exploring the potential 
effects of E. autumnalis plant extracts on stem 
cells. The experimental procedure must focus on 
influencing stem cells’ transduction pathways; 
this is crucial for the induction of cell 
differentiation, improving proliferative capacity, 
expressing articular cartilage anabolic markers 
and inhibiting cartilage mineralization. 
 
Eucomis autumnalis in bone regeneration 
 
Bone healing after fracture has been described in 
four phases. The first phase is the inflammatory 
phase characterized by hematoma formation and 
the release of pro-inflammatory cytokines from 
the surrounding cells. This is followed by the soft 
callus phase, where chondrocytes begin to form 
cartilage tissue that creates a bridge at the 
fracture gap. The next phase is the hard callus 
phase, where the fragile cartilage is transformed 
into woven bone, through the deposition of 
calcium and phosphate into the cartilage [53]. 
Finally, the bone remodeling phase takes place 
where bone is restored to its previous form and 
function. Clinical conditions such as rheumatoid 
arthritis, osteoporosis, diabetes mellitus, or 
ageing have been reported to increase the time it 
takes for a fracture to heal and the possibility of 
complications such as fracture non-union [54]. 
 
E. autumnalis has been found to have anti-
inflammatory activity and inhibition 
of prostaglandin synthesis was investigated by 
assessing the inhibition of the cyclooxygenase 
enzymes COX-1 and COX-2 [12, 16 33]. E. 
autumnalis ethanol extract has shown up to 80 % 
COX-1 inhibition, while the water extract showed 
60 % COX-1 inhibition [33]. Gesternfeld and 
colleagues [55-57] studied the effect of COX 
inhibitors on fracture healing and reported that 
COX-2 inhibitors delayed fracture healing while 
COX-1 inhibitors showed no negative effects on 
bone healing. Other studies have shown that 
different medicinal plants, which also have anti-
inflammatory effects similar to those of E. 
autumnalis, can stimulate osteoblast function, 
and inhibit osteoclast and adipocyte functions 
either alone or in combination [58-60]. 
 
Similarly, E. autumnalis extract may stimulate 
bone formation by virtue of its anti-inflammatory 




Figure 2: Possible proposed function of E. autumnalis 
plant extract in host modulatory therapy in bone and 
tissue regeneration. IL, interleukin; TNF, tumor 
necrosis factor; MMPs, Matrix metalloproteinase; E. 
autumnalis, Eucomis autumnalis 
 
Cytokines, chemokines and prostaglandins have 
been identified as regulators of immune-
inflammatory process in bone and cartilage 
formation. Cytokines like interleukin-1 and tumor 
necrosis factor-α are well known factors that can 
induce bone resorption indirectly in host cells by 
promoting the differentiation and activation of 
osteoclast precursors [61, 62]. Since E. 
autumnalis has anti-inflammatory property, it can 
be employed just like non-steroid anti-
inflammatory drugs in host modulatory therapy 
during intervention for nonsurgical therapy, in 
other to restore balance between pro-
inflammatory mediators, as anti-inflammatory 
mediator and enzyme inhibitors [Fig 2]. 
Furthermore, E. autumnalis may help reduce the 
significant unwanted effects of nonsteroidal anti-
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inflammatory drugs such as hemorrhage, 
gastrointestinal problems and rebound effects in 
patients [63, 64]. The E. autumnalis extract may 
provide a safe and cost-effective alternative 
treatment for bone fracture and complications 
such as non-union. Despite the popular use of 
this medicinal plant for rapid fracture healing, 
there are currently no reported studies 
investigating the effect of this plant extract on 




Generally, with the extensive screening of plants 
used in traditional medicine, evidence of their 
rational use in treating infections, diseases, 
inflammation and other disorders has been 
provided. Despite the huge potential of these 
herbal plants, a definite gap exists in research on 
them - little information is available on indigenous 
South African plants like E. autumnalis. 
 
In nature, E. autumnalis subspecies have a 
widespread distribution, extending across all of 
the provinces of South Africa, as well as 
neighboring countries. A few isolated compounds 
have been recorded in the literature on these 
subspecies and the variations in the 
phytochemical properties of the isolated 
compounds are yet to be investigated.   
The review highlighted some environmental 
factors capable of affecting the availability of E. 
autumnalis species. The effects of these 
environmental contaminants should always be 
considered when reporting on biological activities 
of crude plant extracts. E. autumnalis as a 
medicinal plant has a highly potential role in bone 
formation and cartilage regeneration. Its possible 
role in bone and tissue regeneration is an 
important factor in OA, obesity, osteoporosis 
therapeutics and other inflammatory diseases. 
Further studies should be undertaken 
highlighting more on E autumnalis properties that 
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